The euphoria of hypomethylating agents in MDS and AML: Is it justified? by Sekeres, Mikkael A., MD, MS

Get full text

Are we nearer to curing patients with MDS? by Sekeres, Mikkael A., MD, MS

Get full text

More is better: Combination therapies for myelodysplastic syndromes by Ornstein, Moshe C., MD, MA, Mukherjee, Sudipto, MD, PhD, MPH, Sekeres, Mikkael A., MD, MS

Get full text

Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) after Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Older Patients with Myeloid Malignancies by Nazha, Aziz, Rybicki, Lisa, MS, Abounader, Donna, CCRP, Bolwell, Brian, MD, Dean, Robert M., MD, Ferraro, Christina, RN, BSN, OCN, Gerds, Aaron, MD, Jagadeesh, Deepa, MD, MPH, Hamilton, Betty Ky, MD, Hill, Brian T, Kalaycio, Matt E., MD, Liu, Hein, MD, Pohlman, Brad, MD, Sobecks, Ronald M., MD, Starn, Jamie, BSN RN, Winslow, Victoria, Sekeres, Mikkael, MD, Majhail, Navneet S., MD, MS

Get full text

On-Pathway Regimens Are Associated With Significant Cost Savings for Treatment of Solid Tumors by Fischer, Lindsay

Get full text

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML by Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel

Get full text

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN by Jabbour, Elias, Short, Nicholas J., Montalban-Bravo, Guillermo, Huang, Xuelin, Bueso-Ramos, Carlos, Qiao, Wei, Yang, Hui, Zhao, Chong, Kadia, Tapan, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Estrov, Zeev, Cortes, Jorge, Ravandi, Farhad, Alvarado, Yesid, Komrokji, Rami, Sekeres, Mikkael A., Steensma, David P., DeZern, Amy, Roboz, Gail, Kantarjian, Hagop, Garcia-Manero, Guillermo

Get full text

S10 - Presentation name: Mechanisms and predictors of drug resistance, intolerance to HMAs and clinical management strategies in high-risk MDS: MECHANISMS AND PREDICTORS OF DRUG RESISTANCE, INTOLERANCE TO HMAS AND CLINICAL MANAGEMENT STRATEGIES IN HIGH RISK MDS by Sekeres, Mikkael

Get full text

Presentation name: Mechanisms and predictors of drug resistance, intolerance to HMAs and clinical management strategies in high-risk MDS by Sekeres, Mikkael

Get full text

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials by Platzbecker, U., Fenaux, P., Adès, L., Giagounidis, A., Santini, V., van de Loosdrecht, A.A., Bowen, D., de Witte, T., Garcia-Manero, G., Hellström-Lindberg, E., Germing, U., Stauder, R., Malcovati, L., Sekeres, Mikkael A., Steensma, David P., Gloaguen, S.

Get full text

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML by Gondek, Lukasz P., Tiu, Ramon, O'Keefe, Christine L., Sekeres, Mikkael A., Theil, Karl S., Maciejewski, Jaroslaw P.

Get full text

Time-dependent changes in mortality and transformation risk in MDS by Pfeilstöcker, Michael, Tuechler, Heinz, Sanz, Guillermo, Schanz, Julie, Garcia-Manero, Guillermo, Solé, Francesc, Bennett, John M., Bowen, David, Fenaux, Pierre, Dreyfus, Francois, Kantarjian, Hagop, Kuendgen, Andrea, Malcovati, Luca, Cazzola, Mario, Cermak, Jaroslav, Fonatsch, Christa, Le Beau, Michelle M., Slovak, Marilyn L., Levis, Alessandro, Luebbert, Michael, Maciejewski, Jaroslaw, Machherndl-Spandl, Sigrid, Magalhaes, Silvia M.M., Miyazaki, Yasushi, Sekeres, Mikkael A., Sperr, Wolfgang R., Stauder, Reinhard, Tauro, Sudhir, Valent, Peter, Vallespi, Teresa, van de Loosdrecht, Arjan A., Germing, Ulrich, Haase, Detlef, Greenberg, Peter L.

Get full text

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results by Cortes, Jorge E., Douglas Smith, B., Wang, Eunice S., Merchant, Akil, Oehler, Vivian G., Arellano, Martha, DeAngelo, Daniel J., Pollyea, Daniel A., Sekeres, Mikkael A., Robak, Tadeusz, Ma, Weidong Wendy, Zeremski, Mirjana, Naveed Shaik, M., Douglas Laird, A., O'Connell, Ashleigh, Chan, Geoffrey, Schroeder, Mark A.

Get full text

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS by Malcovati, Luca, Stevenson, Kristen, Papaemmanuil, Elli, Neuberg, Donna, Bejar, Rafael, Boultwood, Jacqueline, Bowen, David T., Campbell, Peter J., Ebert, Benjamin L., Fenaux, Pierre, Haferlach, Torsten, Heuser, Michael, Jansen, Joop H., Komrokji, Rami S., Maciejewski, Jaroslaw P., Walter, Matthew J., Fontenay, Michaela, Garcia-Manero, Guillermo, Graubert, Timothy A., Karsan, Aly, Meggendorfer, Manja, Pellagatti, Andrea, Sallman, David A., Savona, Michael R., Sekeres, Mikkael A., Steensma, David P., Tauro, Sudhir, Thol, Felicitas, Vyas, Paresh, Van de Loosdrecht, Arjan A., Haase, Detlef, Tüchler, Heinz, Greenberg, Peter L., Ogawa, Seishi, Hellstrom-Lindberg, Eva, Cazzola, Mario

Get full text

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML by Jiang, Ying, Dunbar, Andrew, Gondek, Lukasz P., Mohan, Sanjay, Rataul, Manjot, O'Keefe, Christine, Sekeres, Mikkael, Saunthararajah, Yogen, Maciejewski, Jaroslaw P.

Get full text

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial by Garcia-Manero, Guillermo, Mufti, Ghulam J., Fenaux, Pierre, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Ilhan, Osman, Sekeres, Mikkael A., Zeidan, Amer M., Ito, Rodrigo, Zhang, Jennie, Rampersad, Anita, Sinsimer, Daniel, Backstrom, Jay T., Platzbecker, Uwe, Komrokji, Rami S.

Get full text

Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium by Jabbour, Elias J., Garcia‐Manero, Guillermo, Strati, Paolo, Mishra, Asmita, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Kadia, Tapan, Daver, Naval, O'Brien, Susan, Steensma, David P., Sekeres, Mikkael A., Gore, Steven D., Dezern, Amy, Roboz, Gail J., List, Alan F., Kantarjian, Hagop M., Komrokji, Rami S.

Get full text

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort by Stahl, Maximilian, DeVeaux, Michelle, de Witte, Theo, Neukirchen, Judith, Sekeres, Mikkael A., Brunner, Andrew M., Roboz, Gail J., Steensma, David P., Bhatt, Vijaya R., Platzbecker, Uwe, Cluzeau, Thomas, Prata, Pedro H., Itzykson, Raphaël, Fenaux, Pierre, Fathi, Amir T., Smith, Alexandra, Germing, Ulrich, Ritchie, Ellen K., Verma, Vivek, Nazha, Aziz, Maciejewski, Jaroslaw P., Podoltsev, Nikolai A., Prebet, Thomas, Santini, Valeria, Gore, Steven D., Komrokji, Rami S., Zeidan, Amer M.

Get full text

Raising the bar for lower-risk myelodysplastic syndromes by Venugopal, Sangeetha, Sekeres, Mikkael A.

Get full text

Improving clinical trials in higher-risk myelodysplastic syndromes by Sekeres, Mikkael A

Get full text